Cargando…
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
Giant cell tumors of bone (GCTB) are benign and locally destructive tumors that include osteoclast-type multinuclear giant cells. No available treatment is definitively effective in curing GCTB, especially in surgically unresectable cases. Isocitrate dehydrogenase (IDH) mutations have been reported...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317903/ https://www.ncbi.nlm.nih.gov/pubmed/24898068 http://dx.doi.org/10.1111/cas.12413 |
_version_ | 1782355755138023424 |
---|---|
author | Kato Kaneko, Mika Liu, Xing Oki, Hiroharu Ogasawara, Satoshi Nakamura, Takuro Saidoh, Noriko Tsujimoto, Yuta Matsuyama, Yuka Uruno, Akira Sugawara, Masato Tsuchiya, Takashi Yamakawa, Mitsunori Yamamoto, Masayuki Takagi, Michiaki Kato, Yukinari |
author_facet | Kato Kaneko, Mika Liu, Xing Oki, Hiroharu Ogasawara, Satoshi Nakamura, Takuro Saidoh, Noriko Tsujimoto, Yuta Matsuyama, Yuka Uruno, Akira Sugawara, Masato Tsuchiya, Takashi Yamakawa, Mitsunori Yamamoto, Masayuki Takagi, Michiaki Kato, Yukinari |
author_sort | Kato Kaneko, Mika |
collection | PubMed |
description | Giant cell tumors of bone (GCTB) are benign and locally destructive tumors that include osteoclast-type multinuclear giant cells. No available treatment is definitively effective in curing GCTB, especially in surgically unresectable cases. Isocitrate dehydrogenase (IDH) mutations have been reported not only in gliomas and acute myeloid leukemias, but also in cartilaginous tumors and osteosarcomas. However, IDH mutations in GCTB have not been investigated. The IDH mutations are remarkably specific to arginine 132 (R132) in IDH1 and arginine 172 (R172) or arginine 140 (R140) in IDH2; IDH1/2 mutations are known to convert α-ketoglutarate to oncometabolite R(-)-2-hydroxyglutarate. We recently reported that the most frequent IDH mutation in osteosarcomas is IDH2-R172S, which was detected by MsMab-1, a multispecific anti-IDH1/2 mAb. Herein, we newly report the IDH mutations in GCTB, which were stained by MsMab-1 in immunohistochemistry. DNA direct sequencing and subcloning identified IDH mutations of GCTB as IDH2-R172S (16 of 20; 80%). This is the first report to describe IDH mutations in GCTB, and MsMab-1 can be anticipated for use in immunohistochemical determination of IDH1/2 mutation-bearing GCTB. |
format | Online Article Text |
id | pubmed-4317903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43179032015-10-05 Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone Kato Kaneko, Mika Liu, Xing Oki, Hiroharu Ogasawara, Satoshi Nakamura, Takuro Saidoh, Noriko Tsujimoto, Yuta Matsuyama, Yuka Uruno, Akira Sugawara, Masato Tsuchiya, Takashi Yamakawa, Mitsunori Yamamoto, Masayuki Takagi, Michiaki Kato, Yukinari Cancer Sci Report Giant cell tumors of bone (GCTB) are benign and locally destructive tumors that include osteoclast-type multinuclear giant cells. No available treatment is definitively effective in curing GCTB, especially in surgically unresectable cases. Isocitrate dehydrogenase (IDH) mutations have been reported not only in gliomas and acute myeloid leukemias, but also in cartilaginous tumors and osteosarcomas. However, IDH mutations in GCTB have not been investigated. The IDH mutations are remarkably specific to arginine 132 (R132) in IDH1 and arginine 172 (R172) or arginine 140 (R140) in IDH2; IDH1/2 mutations are known to convert α-ketoglutarate to oncometabolite R(-)-2-hydroxyglutarate. We recently reported that the most frequent IDH mutation in osteosarcomas is IDH2-R172S, which was detected by MsMab-1, a multispecific anti-IDH1/2 mAb. Herein, we newly report the IDH mutations in GCTB, which were stained by MsMab-1 in immunohistochemistry. DNA direct sequencing and subcloning identified IDH mutations of GCTB as IDH2-R172S (16 of 20; 80%). This is the first report to describe IDH mutations in GCTB, and MsMab-1 can be anticipated for use in immunohistochemical determination of IDH1/2 mutation-bearing GCTB. BlackWell Publishing Ltd 2014-06 2014-06-04 /pmc/articles/PMC4317903/ /pubmed/24898068 http://dx.doi.org/10.1111/cas.12413 Text en © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made. |
spellingShingle | Report Kato Kaneko, Mika Liu, Xing Oki, Hiroharu Ogasawara, Satoshi Nakamura, Takuro Saidoh, Noriko Tsujimoto, Yuta Matsuyama, Yuka Uruno, Akira Sugawara, Masato Tsuchiya, Takashi Yamakawa, Mitsunori Yamamoto, Masayuki Takagi, Michiaki Kato, Yukinari Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone |
title | Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone |
title_full | Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone |
title_fullStr | Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone |
title_full_unstemmed | Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone |
title_short | Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone |
title_sort | isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317903/ https://www.ncbi.nlm.nih.gov/pubmed/24898068 http://dx.doi.org/10.1111/cas.12413 |
work_keys_str_mv | AT katokanekomika isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT liuxing isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT okihiroharu isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT ogasawarasatoshi isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT nakamuratakuro isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT saidohnoriko isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT tsujimotoyuta isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT matsuyamayuka isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT urunoakira isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT sugawaramasato isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT tsuchiyatakashi isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT yamakawamitsunori isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT yamamotomasayuki isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT takagimichiaki isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone AT katoyukinari isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone |